Anqin Zhang
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer (NCT04975451) | Anqin Zhang | 2021-10-01 |
Track Anqin Zhang automatically
Every clearance here is in the API, with alerts when new ones post.